1.Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy.
Aihua WU ; Yingzhi CHEN ; Hairui WANG ; Ya CHANG ; Meng ZHANG ; Pengfei ZHAO ; Yisi TANG ; Qin XU ; Zhuangzhi ZHU ; Yang CAO ; Yongzhuo HUANG
Acta Pharmaceutica Sinica B 2021;11(11):3622-3635
An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity. A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cancer vaccines and lack of a safe and efficient adjuvant for human use. We discovered a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide, TCS, and a cell-penetrating peptide (CPP), termed an "all-in-one" vaccine, for transcutaneous cancer immunization. The TCS adjuvant effect on antigen presentation was investigated and the antitumor immunity of the vaccines was investigated using the different tumor models. The vaccines were prepared
Result Analysis
Print
Save
E-mail